Betamab Therapeutics Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Private

  • Employees
  • 3

Employees

  • Latest Deal Type
  • Corporate

  • Financing Rounds
  • 1

Betamab Therapeutics General Information

Description

Developer of peptide therapeutics intended to offer intracellular and oral delivery. The company develops betabodies for the discovery and development of specific extracellular and intracellular protein-protein inhibitors synthesized from unnatural L and D amino acids, providing its clients with a new class of therapeutics.

Contact Information

Website
www.betamab.com
Ownership Status
Privately Held (backing)
Financing Status
Corporate Backed or Acquired
Corporate Office
  • C/o Chemical Institute University of Copenhagen
  • Universitetsparken, 5, 3, 01.B304
  • 2100 Copenhagen
  • Denmark
Primary Industry
Drug Delivery
Other Industries
Drug Discovery
Biotechnology
Corporate Office
  • C/o Chemical Institute University of Copenhagen
  • Universitetsparken, 5, 3, 01.B304
  • 2100 Copenhagen
  • Denmark

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Betamab Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Betamab Therapeutics‘s full profile, request access.

Request a free trial

Betamab Therapeutics Executive Team (2)

Name Title Board Seat
Søren Mouritsen MD Chief Executive Officer & Director
Morten Meldal Ph.D Co-Founder, Chief Scientific Officer & Director
To view Betamab Therapeutics’s complete executive team members history, request access »

Betamab Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Betamab Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Betamab Therapeutics‘s full profile, request access.

Request a free trial

Betamab Therapeutics FAQs

  • When was Betamab Therapeutics founded?

    Betamab Therapeutics was founded in 2019.

  • Who is the CEO of Betamab Therapeutics?

    Søren Mouritsen MD is the CEO of Betamab Therapeutics.

  • Where is Betamab Therapeutics headquartered?

    Betamab Therapeutics is headquartered in Copenhagen, Denmark.

  • What is the size of Betamab Therapeutics?

    Betamab Therapeutics has 3 total employees.

  • What industry is Betamab Therapeutics in?

    Betamab Therapeutics’s primary industry is Drug Delivery.

  • Is Betamab Therapeutics a private or public company?

    Betamab Therapeutics is a Private company.

  • What is Betamab Therapeutics’s current revenue?

    The current revenue for Betamab Therapeutics is .

  • Who are Betamab Therapeutics’s investors?

    ALK-Abello has invested in Betamab Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »